Having PBC may increase risk of IBD, but not vice versa: Study
Primary biliary cholangitis (PBC), a rare autoimmune liver disease, shares 10 genetic risk factors with inflammatory bowel disease (IBD), a group of inflammatory conditions…
Cholangitis
New molecule to reduce liver scarring a potential PSC treatment
Researchers at the University of California San Diego (UCSD) have created a molecule, named antisense oligonucleotide (ASO) 56, that is able to potently reduce liver…
Ascletis to stop clinical testing of ASC42 in primary biliary cholangitis
Ascletis Pharma will not to pursue further clinical testing of its experimental oral therapy ASC42 for adults with primary biliary cholangitis (PBC). The…
Elafibranor for PBC may become Genfit’s first approved molecule
Elafibranor, an oral molecule under regulatory review as a new second-line treatment for adults with primary biliary cholangitis (PBC), may become the first candidate…
LB-P8 probiotic on FDA fast track for primary sclerosing cholangitis
The U.S. Food and Drug Administration (FDA) has granted fast track designation to LB-P8, LISCure Biosciences’ experimental live bacterium product that is headed toward…
Phase 1b/2 trial of golexanolone for PBC behavioral symptoms advances
Golexanolone, Umecrine Cognition’s investigational oral therapy, was generally safe and well tolerated in adults with primary biliary cholangitis (PBC) and clinically significant…
FDA to decide on full approval for Ocaliva in treating adults with PBC
The U.S. Food and Drug Administration (FDA) agreed to review an application seeking full and formal approval of Ocaliva (obeticholic acid) as a…
Phase 2 study of LB-P8 for PSC nets FDA clearance
LISCure Biosciences will launch a Phase 2 trial in the United States to evaluate the safety and effectiveness of LB-P8, its live bacterium candidate…
Seladelpar found to reduce disease activity, itch in PBC patients in trial
Daily treatment with seladelpar, CymaBay Therapeutics’ investigational oral candidate for people with primary biliary cholangitis (PBC), was shown to normalize liver biomarkers and…
Patents covering CM-101, potential PSC therapy, given in Brazil, Israel
Chemomab Therapeutics has been awarded patents in Brazil and Israel covering CM-101, the company’s experimental therapy that’s currently being tested in a Phase…
